Xenon Pharmaceuticals
XENE
35.71
-0.70
-1.92%
Xenon Pharmaceuticals
US · XENE
#2361 by market cap
Listed 2015
35.71
-0.70
-1.92%
Live - 5344 symbols - heartbeat 462s ago
· 2026-10-08 10:00
Pre-market
36.01
-1.10%
After-hours
36.00
-1.13%
Overnight
36.40
-0.03%
- Market cap
- 3.46B
- P/E (TTM)i
- -7.53
- P/Bi
- 2.78
- EPSi
- -4.36
- Div yieldi
- 0.00%
- 52W posi
- 0%
Reader sentiment
Are you bullish or bearish on XENE?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 13 analysts
Buy
Avg price target
74.00 +107.2%
Price target rangecurrent 35.71
Low60.00
Avg74.00
High90.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-01 | RBC Capital | -- | BUY | 70.00 |
| 2026-09-21 | Bloom Burton | -- | BUY | 71.00 |
| 2026-09-19 | J.P. Morgan | -- | BUY | 82.00 |
| 2026-09-18 | TD Cowen | -- | BUY | -- |
| 2026-09-18 | Wells Fargo | -- | BUY | 64.00 |
| 2026-09-18 | William Blair | -- | BUY | -- |
| 2026-09-18 | BofA Securities | -- | BUY | -- |
| 2026-09-18 | Baird | -- | BUY | 90.00 |
| 2026-09-18 | Stifel | -- | BUY | -- |
| 2026-09-18 | Needham | -- | BUY | 60.00 |
| 2026-09-18 | H.C. Wainwright | -- | BUY | 74.00 |
| 2026-09-17 | Goldman Sachs | -- | BUY | 75.00 |
| 2026-09-17 | RBC Capital | -- | BUY | 70.00 |
| 2026-09-10 | Wells Fargo | -- | BUY | 69.00 |
| 2026-09-02 | Wells Fargo | -- | BUY | 69.00 |
| 2026-08-13 | Stifel | -- | BUY | 86.00 |
| 2026-08-11 | J.P. Morgan | -- | BUY | 82.00 |
| 2026-08-10 | H.C. Wainwright | -- | BUY | 74.00 |
| 2026-08-07 | BofA Securities | -- | BUY | 77.00 |
| 2026-08-07 | Evercore | -- | BUY | 80.00 |
| 2026-08-07 | Stifel | -- | BUY | 86.00 |
| 2026-08-07 | Needham | -- | BUY | 78.00 |
| 2026-08-07 | H.C. Wainwright | -- | BUY | 74.00 |
| 2026-08-06 | TD Cowen | -- | BUY | -- |
| 2026-08-06 | William Blair | -- | BUY | -- |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-06 | After close | ±8.80% | -1.84% (in line) |
| 2026/Q1 | 2026-05-07 | After close | ±10.12% | +0.79% (in line) |
| 2025/Q3 | 2025-11-03 | After close | ±10.97% | -4.94% (in line) |
| 2025/Q2 | 2025-08-11 | After close | ±9.90% | +5.51% (in line) |
| 2025/Q1 | 2025-05-12 | After close | ±9.76% | -17.43% (beat) |
| 2024/Q4 | 2025-02-27 | After close | ±21.25% | -3.37% (in line) |
| 2024/Q3 | 2024-11-12 | After close | ±9.68% | -3.27% (in line) |
| 2024/Q2 | 2024-08-08 | After close | -- | -3.19% |
| 2024/Q1 | 2024-05-09 | After close | ±11.31% | -4.59% (in line) |
| 2023/Q4 | 2024-02-29 | After close | ±11.45% | -0.76% (in line) |
| 2023/Q3 | 2023-11-08 | After close | ±12.83% | -6.69% (in line) |
| 2023/Q2 | 2023-08-09 | After close | ±11.85% | +8.29% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 10:00:23 · For reference only, not investment advice and not tailored to your situation.